Procept (PRCT) Q1 2026 Earnings Transcript

Procept BioRobotics reported Q1 revenue of $83.1 million, up 20% year over year, with U.S. procedures rising 30% to about 12,200 and gross margin holding at 65%. Management raised new U.S. system ASP expectations to $450,000-$460,000 for the rest of 2026, kept full-year revenue guidance at $390 million-$410 million, and still expects positive adjusted EBITDA in Q4 2026. Offset by wider losses and higher operating expenses, the quarter also brought EAU guideline support for Aquablation, FDA clearance for FirstAssist AI, and early U.K. system sales.

Analysis

PRCT is at an inflection where the market will likely focus less on the headline growth rate and more on whether the company can convert capital placement into durable utilization. The key second-order signal is that pricing is improving without a dependence on large IDN wins, which suggests the installed base mix is still skewing toward smaller, less price-sensitive accounts; that is supportive near term, but it also means the eventual upside from broader IDN penetration is not yet in the numbers. The other subtle positive is that the replacement cycle has started earlier than expected, which can become a higher-quality revenue stream because it is less dependent on first-time clinical adoption and more on installed-base refresh economics.

The risk is that the commercial reset creates an apparent acceleration in the second half that is really just a normalization of a weak first half. If procedure growth does not re-accelerate by late Q2/early Q3, investors may start discounting the guide as being back-half loaded for execution rather than demand, especially given the company is still posting meaningful operating losses and tariff pressure is rising. The margin story is constructive, but because it is being driven partly by price discipline, it is more fragile than volume-led margin expansion; if mix shifts back toward larger IDNs or competitive pricing intensifies, gross margin leverage could stall.

The best contrarian read is that consensus may be underestimating how powerful the combination of guideline support, software differentiation, and launch-team discipline can be when layered onto a growing installed base. However, consensus may also be overestimating how quickly the market can absorb a new sales operating model while maintaining procedure momentum. The setup is therefore more attractive as a medium-term story than a near-term one: the catalyst window is Q2/Q3 procedure prints plus any evidence that launch-team placements are converting into above-average utilization rather than just better ASPs.

Key Decisions for Investors

• Long PRCT on weakness, but only with a 6-9 month horizon: the risk/reward improves if the stock stays rangebound while Q2/Q3 data proves procedure re-acceleration; downside is sharp if utilization fails to inflect by the end of Q2.
• For traders, buy PRCT call spreads into Q2 earnings or late-Q2 updates if the shares trade off on 'back-half loaded' skepticism; the upside case is a re-rating on evidence that pricing and procedures are both inflecting, not just systems ASP.
• Pair trade: long PRCT / short a diversified medtech basket or a slower-growth surgical device peer, targeting relative outperformance if launch-team economics and replacement-cycle monetization show up in the next 2 quarters.
• Do not chase the move on headline gross margin alone; wait for a confirmation point in procedure growth. If U.S. procedures re-accelerate sequentially in Q2, add aggressively; if not, expect multiple compression despite the strong guide.